DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with relapsed cancers: CBL0137 trial launches
Disease control Recruiting nowThis study tests a drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the safest dose and see if the drug can shrink tumors by blocking signals that he…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
Radioactive therapy targets hard-to-treat brain tumors in early trial
Disease control Recruiting nowThis early-phase study tests whether a radioactive drug called 177Lu-PSMA-617 is safe for people with a fast-growing type of brain cancer (IDH wild type glioma). About 20 adults whose tumors express a protein called PSMA will receive the drug after standard treatments. The main g…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC